Cancer Drug Parity Act of 2019

H.R. 1730/S. 670, STAT Act H.R. 482/S. 350, Newborn Screening Reauthorization Act

Client expense: Not reported · Firm income: Not reported

H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 985, Fair Access for Safe and Timely (FAST) Generics Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 986, Protecting American with Preexisting Conditions Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1010, Short-Term, Limited Duration Insurance (STLDI), regarding all bio-pharmaceutical related provisions. H.R. 1323, Rural Hospital Frontier Fairness Act, regarding all bio-pharmaceutical related provisions. H.R. 1385, State Allowance for a Variety of Exchanges (SAVE) Act, regarding all bio-pharmaceutical related provisions. H.R. 1386, Expanded Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act, regarding all bio-pharmaceutical related provisions. H.R. 1409, Transparency in All Health Care Pricing Act, regarding all bio-pharmaceutical related provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions. H.R. 1478, Insulin importation, regarding all bio-pharmaceutical related provisions. H.R. 1503, Orange Book Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1506, Fair and Immediate Release (FAIR) of Generics Act, regarding all bio-pharmaceutical related provisions. H.R. 1520, Purple Book Continuity Act, regarding all bio-pharmaceutical related provisions. H.R. 2011, Protecting Access to Biosimilars Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2038, State-based , Market-Oriented, Prescription Drug Negotiations Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2064, Product Sample reporting, regarding all bio-pharmaceutical related provisions. S. 61, Safe and Affordable Drugs from Canada Act, regarding all bio-pharmaceutical related provisions. S. 97, Affordable and Safe Drug Importation Act, regarding all bio-pharmaceutical related provisions. S. 102, Prescription Drug Price Relief Act, regarding all bio-pharmaceutical related provisions. S. 344/H.R. 990, Hatch-Waxman Integrity Act, regarding all bio-pharmaceutical related provisions. S. 366/H.R. 1188, FLAT Prices Act- Reduced exclusivity period for certain price hikes, regarding all bio-pharmaceutical related provisions. S. 418, FDA Accountability for Public Safety Act, regarding all bio-pharmaceutical related provisions. S. 419, Protecting Americans from Dangerous Opioids Act, regarding all bio-pharmaceutical related provisions. S. 637, CURE High Drug Prices Act, regarding all bio-pharmaceutical related provisions. S. 657, Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. S. 658, Accelerated Drug Approval for Prescription Therapies Act, regarding all bio-pharmaceutical related provisions. S. 659, Biologic Patent Transparency Act, regarding all bio-pharmaceutical related provisions. S. 660, Transparency in Petitions Act, regarding all bio-pharmaceutical related provisions. S. 709, Establishes public dashboard for price and utilization of drugs purchased by federal programs, regarding all bio-pharmaceutical related provisions. S. 741 /H.R. 1730, Cancer Drug Parity Act, regarding all bio-pharmaceutical related provisions. S. 844, Short Competition Act, regarding all bio-pharmaceutical related provisions. S. 977, Transparent Drug Pricing Act of 2019, regarding all bio-pharmaceutical related provisions. S. 989, STEER Act, regarding all bio-pharmaceutical related provisions. S. 1140, A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009, regarding all bio-pharmaceutical related provisions. S.1169, FDA citizen petition, regarding all bio-pharmaceutical related provisions. S. 1209, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications, regarding all bio-pharmaceutical related provisions. H.R. 2115, Public Disclosure of Drug Discounts Act, regarding all bio-pharmaceutical related provisions H.R.2296/S.1391, FAIR Drug Pricing Act, regarding all bio-pharmaceutical related provisions H.R.2700, Lowering Prescription Drug Costs and Extending Community Health Centers and other Health Priorities Act, regarding all bio-pharmaceutical related provisions H.R. 3223, Pharmacy Benefit Manager Accountability Study Act, regarding all bio-pharmaceutical related provisions S. 1361/H.R.2584, Preventive Health Savings Act, regarding all bio-pharmaceutical related provisions S. 1437, DTC Act, regarding all bio-pharmaceutical related provisions S.1532, Pharmacy Benefit Managers Accountability Study Act, regarding all bio-pharmaceutical related provisions S.1636, Ensuring Innovation Act, regarding all bio-pharmaceutical related provisions S. 1664, Prescription Drug Price Reporting Act, regarding all bio-pharmaceutical related provisions S. 1801, Affordable Medications Act, regarding all bio-pharmaceutical related provisions S. 1895, Lowering Health Costs Act, regarding all bio-pharmaceutical related provisions S. 1897, a bill to establish a process for updating the labeling of certain drugs with outdated labeling, regarding all bio-pharmaceutical related provisions S. 1897/H.R. 3523, End Price Gouging for Medications Act, regarding all bio-pharmaceutical related provisions S. 2004, Emergency Access to Insulin Act, regarding all bio-pharmaceutical related provisions H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions H.R 748/S. 3548, Coronavirus Aid, Relief and Economic Security Act (CARES Act), regarding all bio-pharmaceutical provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, regarding all bio-pharmaceutical related provisions

Client expense: $1,090,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)

Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, cancer survivorship, federal health care programs, genetic information, cancer, nutrition, tanning beds, clinical trials, skin cancer, cannabis research, and wellness, including: HR 6514, Worker Health Coverage Protection Act HR 1425, Patient Protection and Affordable Care Enhancement Act Issues related to regulations for implementing section 1557 of the Affordable Care Act on anti-discrimination HR 6800, Health and Economic Recovery Omnibus Emergency Solutions Act or The HEROES Act Issues related to the Senate HELP Committee initiative on preparing for future pandemics. Regulatory issues related to telehealth Issues related to surprise medical billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019; Issues relating to curbing health care costs; H.R.647 & S. 2080, the Palliative Care and Hospice Education and Training Act; Anti-cancer medication cost-sharing parity respecting H.R. 1409; A national family caregiving strategy respecting S. 1719 and H.R. 1028; Access to medicines respecting FDA implementation of right to try law; Introduction of the S. 3404 & H.R. 6102, Verifying Accurate Leading-edge IVCT Development Act of 2020 or the VALID Act of 2020; H. Res. 282, supporting initiatives to encourage parents and guardians to take measures to prevent sunburns in minors they care for; H.R. 1966 & S 946, the Henrietta Lacks Enhancing Cancer Research Act of 2019, regarding decreasing disparities in access to cancer clinical trials; Additional issues related to reducing health disparities in cancer clinical trials; Issues related to capturing racial and ethnic data demographic data for communities disproportionately affected by coronavirus; H.R. 2222 and S. 1107, the Women and Lung Cancer Research and Preventative Services Act; H.Res. 14 & S.Res. 223, Expressing support for the designation of DIPG Awareness Day H.R. 1730 and S. 741, the Cancer Drug Parity Act; Cannabis research issues, including S. 2032 Cannabidiol and Marihuana Research Expansion Act and S. 2400Expanding Cannabis Research and Information Act ; H.R. 4078 & S. 2424 EARLY Act Reauthorization of 2019 S. 2497, the Dependent Income Exclusion Act; Issues related to HHS regulation of prescription drug prices and costs; H.R. 4439, Creating Hope Reauthorization Act; H.R. 1730 and S. 741, the Cancer Drug Parity Act; H.R. 6556, the Gabriella Miller Kids First Research Act 2.0; H.R. 4439 & S. 4010, the Creating Hope Reauthorization Act; H.R.6666 & S. 4315, the COVID-19 Testing, Reaching, And Contacting Everyone (TRACE) Act, bill related to support needed data collection efforts to begin to contain coronavirus; Issues related to cancer survivorship and transitions of care from oncology treatment back to primary care; Issues related to improving data collection during the COVID-19 pandemic; and H.Res 1125, which expresses support for prioritizing racial and ethnic diversity in clinical trials for therapies, diagnostics in clinical trials for therapies, diagnostics, and vaccines for COVID -19. S 4557, COVID Enrollment Response Act (Sen. Baldwin)

Client expense: $490,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Energy, Dept of, Environmental Protection Agency (EPA), Federal Reserve System, Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), Veterans Affairs, Dept of (VA), White House Office

HR 1730/S.741 Cancer Issues - Multiple Myeloma

Client expense: $69,489 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 1730/S.741 Cancer Issues - Multiple Myeloma

Client expense: $66,733 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 3630, No Surprises Act; S. 1531, Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019; S. 1895, Lower Health Care Costs Act; H.R. 5800, Ban Surprise Billing Act; H.R. 5826 Consumer Protections Against Surprise Medical Bills Act; H.R. 1730/S 741, the Cancer Drug Parity Act; Texas v US lawsuit implications for protections for people with pre-existing conditions; federal regulation of Short-Term Limited-Duration Insurance (STLDI) and other junk insurance;

Client expense: $80,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Access to Breast Cancer Diagnosis (ABCD) Act (S. 3216 / H.R. 2428) Implementation of the Affordable Care Act Surprise medical billing Cancer Drug Parity Act (S. 741 / H.R. 1730) S. 4557, The COVER Act Policies related to COVID and immunocompromised populations Policies related to co-pay assistance programs

Client expense: Not reported · Firm income: $40,000

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Natl Institutes of Health (NIH), SENATE

H.R.1730/S.741 - Cancer Drug Parity Act H.R.2428/S.1632 - Access to Breast Cancer Diagnosis Act H.R.2777/S.1936 - Protecting Access to Lifesaving Screenings Act Efforts to reduce surprise medical billing Public and private insurance adjustments and other policy changes due to the COVID-19 emergency, including those impacting the immunocompromised populations Implementation of the Affordable Care Act Policies related to co-pay assistance programs

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, cancer survivorship, federal health care programs, genetic information, cancer, nutrition, tanning beds, clinical trials, skin cancer, cannabis research, and wellness, including: HR 6514, Worker Health Coverage Protection Act HR 1425, Patient Protection and Affordable Care Enhancement Act Issues related to regulations for implementing section 1557 of the Affordable Care Act on anti-discrimination HR 6800, Health and Economic Recovery Omnibus Emergency Solutions Act or The HEROES Act Issues related to the Senate HELP Committee initiative on preparing for future pandemics. Regulatory issues related to telehealth Issues related to surprise medical billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019; Issues relating to curbing health care costs; H.R.647 & S. 2080, the Palliative Care and Hospice Education and Training Act; Anti-cancer medication cost-sharing parity respecting H.R. 1409; A national family caregiving strategy respecting S. 1719 and H.R. 1028; Access to medicines respecting FDA implementation of right to try law; Introduction of the S. 3404 & H.R. 6102, Verifying Accurate Leading-edge IVCT Development Act of 2020 or the VALID Act of 2020; H. Res. 282, supporting initiatives to encourage parents and guardians to take measures to prevent sunburns in minors they care for; H.R. 1966 & S 946, the Henrietta Lacks Enhancing Cancer Research Act of 2019, regarding decreasing disparities in access to cancer clinical trials; Additional issues related to reducing health disparities in cancer clinical trials; Issues related to capturing racial and ethnic data demographic data for communities disproportionately affected by coronavirus; H.R. 2222 and S. 1107, the Women and Lung Cancer Research and Preventative Services Act; H.Res. 14 & S.Res. 223, Expressing support for the designation of DIPG Awareness Day H.R. 1730 and S. 741, the Cancer Drug Parity Act; Cannabis research issues, including S. 2032 Cannabidiol and Marihuana Research Expansion Act and S. 2400Expanding Cannabis Research and Information Act ; H.R. 4078 & S. 2424 EARLY Act Reauthorization of 2019 S. 2497, the Dependent Income Exclusion Act; Issues related to HHS regulation of prescription drug prices and costs; H.R. 4439, Creating Hope Reauthorization Act; H.R. 1730 and S. 741, the Cancer Drug Parity Act; H.R. 6556, the Gabriella Miller Kids First Research Act 2.0; H.R. 4439 & S. 4010, the Creating Hope Reauthorization Act; H.R.6666 & S. 4315, the COVID-19 Testing, Reaching, And Contacting Everyone (TRACE) Act, bill related to support needed data collection efforts to begin to contain coronavirus; Issues related to cancer survivorship and transitions of care from oncology treatment back to primary care; Issues related to improving data collection during the COVID-19 pandemic; and H.Res 1125, which expresses support for prioritizing racial and ethnic diversity in clinical trials for therapies, diagnostics in clinical trials for therapies, diagnostics, and vaccines for COVID -19. S 4557, COVID Enrollment Response Act (Sen. Baldwin)

Client expense: $490,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Energy, Dept of, Environmental Protection Agency (EPA), Federal Reserve System, Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), Veterans Affairs, Dept of (VA), White House Office

Monitoring healthcare regulations and legislation; Palliative Care Hospice Education & Treatment Act PCHETA (H.R 647/S 2080); Cancer Drug Parity Act (H.R. 1730/S. 741); Lymphedema Treatment Act (H.R. 1948/S. 518); Preventing Opportunities for Teen E-Cigarette and Tobacco Addiction (PROTECT) Act" (H.R.2111/S.1048; Title VIII funding

Client expense: $43,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, White House Office

Cancer Drug Parity Act (S.741 / H.R.1730) Resident Physician Shortage Reduction Act of 2019 (S. 348/H.R. 1763) Newborn Screening Saves Lives Reauthorization Act of 2019 (H.R. 2507) Implementation of Patient Protection and Affordable Care Act (P.L. 111-148) Hematology and oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Reimbursement for CAR-T/cellular and gene therapies Issues impacting opioid access/use for patients with hematologic diseases and disorders Issues impacting blood safety/shortages Issues related to convalescent plasma Healthcare Workforce Resilience Act (H.R. 6788/S. 3599) Coronavirus Provider Protection Act (H.R. 7059) Issues related to health equity/disproportionate impact of COVID-19 on minority populations Health Care at Home Act (H.R. 6644/S. 3741) Withdrawal of the United States from the World Health Organization (WHO)

Client expense: $30,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), White House Office

H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 985, Fair Access for Safe and Timely (FAST) Generics Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 986, Protecting American with Preexisting Conditions Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1010, Short-Term, Limited Duration Insurance (STLDI), regarding all bio-pharmaceutical related provisions. H.R. 1323, Rural Hospital Frontier Fairness Act, regarding all bio-pharmaceutical related provisions. H.R. 1385, State Allowance for a Variety of Exchanges (SAVE) Act, regarding all bio-pharmaceutical related provisions. H.R. 1386, Expanded Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act, regarding all bio-pharmaceutical related provisions. H.R. 1409, Transparency in All Health Care Pricing Act, regarding all bio-pharmaceutical related provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions. H.R. 1478, Insulin importation, regarding all bio-pharmaceutical related provisions. H.R. 1503, Orange Book Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1506, Fair and Immediate Release (FAIR) of Generics Act, regarding all bio-pharmaceutical related provisions. H.R. 1520, Purple Book Continuity Act, regarding all bio-pharmaceutical related provisions. H.R. 2011, Protecting Access to Biosimilars Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2038, State-based , Market-Oriented, Prescription Drug Negotiations Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2064, Product Sample reporting, regarding all bio-pharmaceutical related provisions. S. 61, Safe and Affordable Drugs from Canada Act, regarding all bio-pharmaceutical related provisions. S. 97, Affordable and Safe Drug Importation Act, regarding all bio-pharmaceutical related provisions. S. 102, Prescription Drug Price Relief Act, regarding all bio-pharmaceutical related provisions. S. 344/H.R. 990, Hatch-Waxman Integrity Act, regarding all bio-pharmaceutical related provisions. S. 366/H.R. 1188, FLAT Prices Act- Reduced exclusivity period for certain price hikes, regarding all bio-pharmaceutical related provisions. S. 418, FDA Accountability for Public Safety Act, regarding all bio-pharmaceutical related provisions. S. 419, Protecting Americans from Dangerous Opioids Act, regarding all bio-pharmaceutical related provisions. S. 637, CURE High Drug Prices Act, regarding all bio-pharmaceutical related provisions. S. 657, Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. S. 658, Accelerated Drug Approval for Prescription Therapies Act, regarding all bio-pharmaceutical related provisions. S. 659, Biologic Patent Transparency Act, regarding all bio-pharmaceutical related provisions. S. 660, Transparency in Petitions Act, regarding all bio-pharmaceutical related provisions. S. 709, Establishes public dashboard for price and utilization of drugs purchased by federal programs, regarding all bio-pharmaceutical related provisions. S. 741 /H.R. 1730, Cancer Drug Parity Act, regarding all bio-pharmaceutical related provisions. S. 844, Short Competition Act, regarding all bio-pharmaceutical related provisions. S. 977, Transparent Drug Pricing Act of 2019, regarding all bio-pharmaceutical related provisions. S. 989, STEER Act, regarding all bio-pharmaceutical related provisions. S. 1140, A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009, regarding all bio-pharmaceutical related provisions. S.1169, FDA citizen petition, regarding all bio-pharmaceutical related provisions. S. 1209, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications, regarding all bio-pharmaceutical related provisions. H.R. 2115, Public Disclosure of Drug Discounts Act, regarding all bio-pharmaceutical related provisions H.R.2296/S.1391, FAIR Drug Pricing Act, regarding all bio-pharmaceutical related provisions H.R.2700, Lowering Prescription Drug Costs and Extending Community Health Centers and other Health Priorities Act, regarding all bio-pharmaceutical related provisions H.R. 3223, Pharmacy Benefit Manager Accountability Study Act, regarding all bio-pharmaceutical related provisions S. 1361/H.R.2584, Preventive Health Savings Act, regarding all bio-pharmaceutical related provisions S. 1437, DTC Act, regarding all bio-pharmaceutical related provisions S.1532, Pharmacy Benefit Managers Accountability Study Act, regarding all bio-pharmaceutical related provisions S.1636, Ensuring Innovation Act, regarding all bio-pharmaceutical related provisions S. 1664, Prescription Drug Price Reporting Act, regarding all bio-pharmaceutical related provisions S. 1801, Affordable Medications Act, regarding all bio-pharmaceutical related provisions S. 1895, Lowering Health Costs Act, regarding all bio-pharmaceutical related provisions S. 1897, a bill to establish a process for updating the labeling of certain drugs with outdated labeling, regarding all bio-pharmaceutical related provisions S. 1897/H.R. 3523, End Price Gouging for Medications Act, regarding all bio-pharmaceutical related provisions S. 2004, Emergency Access to Insulin Act, regarding all bio-pharmaceutical related provisions H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions H.R 748/S. 3548, Coronavirus Aid, Relief and Economic Security Act (CARES Act), regarding all bio-pharmaceutical provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, regarding all bio-pharmaceutical related provisions

Client expense: $1,090,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)

PL 109-417 - Pandemic and All-Hazards Preparedness Act (PAHPA) PL 116-127/H.R. 6201 - Families First Coronavirus Response Act H.R. 6365/S. 3559 - The Immediate Relief for Rural Facilities and Providers Act H.R. 748/S. 3548 - Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 7059: Coronavirus Provider Protection Act S. 1895 - Lower Health Care Costs Act H.R. 5800 - Ban Surprise Billing Act H.R. 5826 - Consumer Protections Against Surprise Medical Bills Act H.R. 3630 - No Surprises Act H. R. 8 - Bipartisan Background Checks Act of 2019 H. R. 1418 - Competitive Health Insurance Reform Act of 2019 S. 668/H.R. 1570 - Removing Barriers to Colorectal Cancer Screening Act of 2019 S. 966 - Medicare Care Coordination Improvement Act of 2019 S. 2372 - VA MISSION Act of 2018 S. 741/H. R. 1730 - Cancer Drug Parity Act of 2019 H. R. 1379 - Ensuring Lasting Smiles Act H. R. 207 - Stop the Violence Act of 2019 H. R. 1841 - Ensuring Access to General Surgery Act of 2019 (and Senate version reintroduction) H. R. 1041 - Critical Access Hospital Relief Act of 2019 H.R. 3656/S. 1350 - ACCESS Act of 2019 H.R. 861 - End Surprise Billing Act H.R. 3630 - No Surprises Act H.R. 3502 - Protecting People from Surprise Medical Bills Act H.R. 2550 - Prevent BLEEDing Act of 2019 H. R. 2143 - Promoting Integrity in Medicare Act of 2019 H. R. 3107 - Improving Seniors' Timely Access to Care Act of 2019 H. R. 1332 - Fair Care Act of 2019 H.R. 2464 - End the Cycle of Violence Act of 2019 S. 1895 - Lower Health Care Costs Act S. 967 - Reducing Costs for Out of Network Services Act S. 1266 - Protecting Patients from Surprise Medical Bills Act S. 1531 - Stopping the Outrageous Practice of Surprise Bills Act S. 1607 - Medical Billing Fairness Act H. R. - 1763/S. 348 - Resident's Physician Shortage Reduction Act S. 1350 - Good Samaritan Health Professionals Act H. R. 2689/S. 1438 - Breast Cancer Research Stamp reauthorization H.R. 4350/S. 3085 - Ambulatory Surgical Center Quality and Access Act of 2019 H.R. 5855 - Bipartisan Solution to Cyclical Violence Act of 2020 H.R. 6953 - Pandemic Responder Service Award Act H.R. 6644/S. 3741 - Telehealth legislation/The Health Care at Home Act H.R. 6365/S. 3559 - Immediate Relief for Rural Facilities Act H.R. 7255 - Coronavirus Health Care Worker Wellness Act S. 3741 - Health Care at Home Act S. 3750/H.R. 6837 - Medicare Accelerated and Advanced Payments Improvement Act H.R.133 - Consolidated Appropriations Act, 2021 Phase 4 COVID-19 relief legislation H. R. 8702 - Holding Providers Harmless from Medicare Cuts During COVID-19 Act Federal Incentive Programs COVID-Safely Returning to Work and School in the Fall COVID-PPE Shortages Mental Health Issues Health Care Disparities Cures 2.0 E/M Global Code Issues Unique Patient Identifier Lower Health Care Costs Act Compromise Bleeding Control for the Injured (Stop The Bleed campaign) Qualified clinical data registry (QCDR) Firearms Safety and Research MACRA Implementation Merit-based Incentive Payment Systems (MIPS) MIPS Value Pathways (MVPs) Alternative Payment Models (APM) Outpatient Prospective Payment System (OPPS) Common Rule Medicare for All National Trauma Systems Legislation Drug Pricing Patient-Centered Outcomes Research Institute (PCORI) Measuring Surgical Quality Medicare Physician Reimbursement Cancer Research and Funding Trauma Research and Funding Opioids/Pain Management Legislation ACS THRIVE (Transforming Health care Resources to Increase Value and Efficiency) Reauthorization of Patient-Centered Outcomes Research Institute (PCORI) 2020 CMS Proposed Fee Schedule Rare earth magnet legislation

Client expense: $10,400 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE, Veterans Affairs, Dept of (VA)

PL 109-417 - Pandemic and All-Hazards Preparedness Act (PAHPA) PL 116-127/H.R. 6201 - Families First Coronavirus Response Act H.R. 6365/S. 3559 - The Immediate Relief for Rural Facilities and Providers Act H.R. 748/S. 3548 - Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 7059: Coronavirus Provider Protection Act S. 1895 - Lower Health Care Costs Act H.R. 5800 - Ban Surprise Billing Act H.R. 5826 - Consumer Protections Against Surprise Medical Bills Act H.R. 3630 - No Surprises Act H. R. 8 - Bipartisan Background Checks Act of 2019 H. R. 1418 - Competitive Health Insurance Reform Act of 2019 S. 668/H.R. 1570 - Removing Barriers to Colorectal Cancer Screening Act of 2019 S. 966 - Medicare Care Coordination Improvement Act of 2019 S. 2372 - VA MISSION Act of 2018 S. 741/H. R. 1730 - Cancer Drug Parity Act of 2019 H. R. 1379 - Ensuring Lasting Smiles Act H. R. 207 - Stop the Violence Act of 2019 H. R. 1841 - Ensuring Access to General Surgery Act of 2019 (and Senate version reintroduction) H. R. 1041 - Critical Access Hospital Relief Act of 2019 H.R. 3656/S. 1350 - ACCESS Act of 2019 H.R. 861 - End Surprise Billing Act H.R. 3630 - No Surprises Act H.R. 3502 - Protecting People from Surprise Medical Bills Act H.R. 2550 - Prevent BLEEDing Act of 2019 H. R. 2143 - Promoting Integrity in Medicare Act of 2019 H. R. 3107 - Improving Seniors' Timely Access to Care Act of 2019 H. R. 1332 - Fair Care Act of 2019 H.R. 2464 - End the Cycle of Violence Act of 2019 S. 1895 - Lower Health Care Costs Act S. 967 - Reducing Costs for Out of Network Services Act S. 1266 - Protecting Patients from Surprise Medical Bills Act S. 1531 - Stopping the Outrageous Practice of Surprise Bills Act S. 1607 - Medical Billing Fairness Act H. R. - 1763/S. 348 - Resident's Physician Shortage Reduction Act S. 1350 - Good Samaritan Health Professionals Act H. R. 2689/S. 1438 - Breast Cancer Research Stamp reauthorization H.R. 4350/S. 3085 - Ambulatory Surgical Center Quality and Access Act of 2019 H.R. 5855 - Bipartisan Solution to Cyclical Violence Act of 2020 H.R. 6953 - Pandemic Responder Service Award Act H.R. 6644/S. 3741 - Telehealth legislation/The Health Care at Home Act H.R. 6365/S. 3559 - Immediate Relief for Rural Facilities Act H.R. 7255 - Coronavirus Health Care Worker Wellness Act S. 3741 - Health Care at Home Act S. 3750/H.R. 6837 - Medicare Accelerated and Advanced Payments Improvement Act H.R.133 - Consolidated Appropriations Act, 2021 Phase 4 COVID-19 relief legislation H. R. 8702 - Holding Providers Harmless from Medicare Cuts During COVID-19 Act Federal Incentive Programs COVID-Safely Returning to Work and School in the Fall COVID-PPE Shortages Mental Health Issues Health Care Disparities Cures 2.0 E/M Global Code Issues Unique Patient Identifier Lower Health Care Costs Act Compromise Bleeding Control for the Injured (Stop The Bleed campaign) Qualified clinical data registry (QCDR) Firearms Safety and Research MACRA Implementation Merit-based Incentive Payment Systems (MIPS) MIPS Value Pathways (MVPs) Alternative Payment Models (APM) Outpatient Prospective Payment System (OPPS) Common Rule Medicare for All National Trauma Systems Legislation Drug Pricing Patient-Centered Outcomes Research Institute (PCORI) Measuring Surgical Quality Medicare Physician Reimbursement Cancer Research and Funding Trauma Research and Funding Opioids/Pain Management Legislation ACS THRIVE (Transforming Health care Resources to Increase Value and Efficiency) Reauthorization of Patient-Centered Outcomes Research Institute (PCORI) 2020 CMS Proposed Fee Schedule Rare earth magnet legislation

Client expense: $10,400 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE, Veterans Affairs, Dept of (VA)

PL 109-417 - Pandemic and All-Hazards Preparedness Act (PAHPA) PL 116-127/H.R. 6201 - Families First Coronavirus Response Act H.R. 6365/S. 3559 - The Immediate Relief for Rural Facilities and Providers Act H.R. 748/S. 3548 - Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 7059: Coronavirus Provider Protection Act S. 1895 - Lower Health Care Costs Act H.R. 5800 - Ban Surprise Billing Act H.R. 5826 - Consumer Protections Against Surprise Medical Bills Act H.R. 3630 - No Surprises Act H. R. 8 - Bipartisan Background Checks Act of 2019 H. R. 1418 - Competitive Health Insurance Reform Act of 2019 S. 668/H.R. 1570 - Removing Barriers to Colorectal Cancer Screening Act of 2019 S. 966 - Medicare Care Coordination Improvement Act of 2019 S. 2372 - VA MISSION Act of 2018 S. 741/H. R. 1730 - Cancer Drug Parity Act of 2019 H. R. 1379 - Ensuring Lasting Smiles Act H. R. 207 - Stop the Violence Act of 2019 H. R. 1841 - Ensuring Access to General Surgery Act of 2019 (and Senate version reintroduction) H. R. 1041 - Critical Access Hospital Relief Act of 2019 H.R. 3656/S. 1350 - ACCESS Act of 2019 H.R. 861 - End Surprise Billing Act H.R. 3630 - No Surprises Act H.R. 3502 - Protecting People from Surprise Medical Bills Act H.R. 2550 - Prevent BLEEDing Act of 2019 H. R. 2143 - Promoting Integrity in Medicare Act of 2019 H. R. 3107 - Improving Seniors' Timely Access to Care Act of 2019 H. R. 1332 - Fair Care Act of 2019 H.R. 2464 - End the Cycle of Violence Act of 2019 S. 1895 - Lower Health Care Costs Act S. 967 - Reducing Costs for Out of Network Services Act S. 1266 - Protecting Patients from Surprise Medical Bills Act S. 1531 - Stopping the Outrageous Practice of Surprise Bills Act S. 1607 - Medical Billing Fairness Act H. R. - 1763/S. 348 - Resident's Physician Shortage Reduction Act S. 1350 - Good Samaritan Health Professionals Act H. R. 2689/S. 1438 - Breast Cancer Research Stamp reauthorization H.R. 4350/S. 3085 - Ambulatory Surgical Center Quality and Access Act of 2019 H.R. 5855 - Bipartisan Solution to Cyclical Violence Act of 2020 H.R. 6953 - Pandemic Responder Service Award Act H.R. 6644/S. 3741 - Telehealth legislation/The Health Care at Home Act H.R. 6365/S. 3559 - Immediate Relief for Rural Facilities Act H.R. 7255 - Coronavirus Health Care Worker Wellness Act S. 3741 - Health Care at Home Act S. 3750/H.R. 6837 - Medicare Accelerated and Advanced Payments Improvement Act H.R.133 - Consolidated Appropriations Act, 2021 Phase 4 COVID-19 relief legislation H. R. 8702 - Holding Providers Harmless from Medicare Cuts During COVID-19 Act Federal Incentive Programs COVID-Safely Returning to Work and School in the Fall COVID-PPE Shortages Mental Health Issues Health Care Disparities Cures 2.0 E/M Global Code Issues Unique Patient Identifier Lower Health Care Costs Act Compromise Bleeding Control for the Injured (Stop The Bleed campaign) Qualified clinical data registry (QCDR) Firearms Safety and Research MACRA Implementation Merit-based Incentive Payment Systems (MIPS) MIPS Value Pathways (MVPs) Alternative Payment Models (APM) Outpatient Prospective Payment System (OPPS) Common Rule Medicare for All National Trauma Systems Legislation Drug Pricing Patient-Centered Outcomes Research Institute (PCORI) Measuring Surgical Quality Medicare Physician Reimbursement Cancer Research and Funding Trauma Research and Funding Opioids/Pain Management Legislation ACS THRIVE (Transforming Health care Resources to Increase Value and Efficiency) Reauthorization of Patient-Centered Outcomes Research Institute (PCORI) 2020 CMS Proposed Fee Schedule Rare earth magnet legislation

Client expense: $308,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE, Veterans Affairs, Dept of (VA)

PL 109-417 - Pandemic and All-Hazards Preparedness Act (PAHPA) PL 116-127/H.R. 6201 - Families First Coronavirus Response Act H.R. 6365/S. 3559 - The Immediate Relief for Rural Facilities and Providers Act H.R. 748/S. 3548 - Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 7059: Coronavirus Provider Protection Act S. 1895 - Lower Health Care Costs Act H.R. 5800 - Ban Surprise Billing Act H.R. 5826 - Consumer Protections Against Surprise Medical Bills Act H.R. 3630 - No Surprises Act H. R. 8 - Bipartisan Background Checks Act of 2019 H. R. 1418 - Competitive Health Insurance Reform Act of 2019 S. 668/H.R. 1570 - Removing Barriers to Colorectal Cancer Screening Act of 2019 S. 966 - Medicare Care Coordination Improvement Act of 2019 S. 2372 - VA MISSION Act of 2018 S. 741/H. R. 1730 - Cancer Drug Parity Act of 2019 H. R. 1379 - Ensuring Lasting Smiles Act H. R. 207 - Stop the Violence Act of 2019 H. R. 1841 - Ensuring Access to General Surgery Act of 2019 (and Senate version reintroduction) H. R. 1041 - Critical Access Hospital Relief Act of 2019 H.R. 3656/S. 1350 - ACCESS Act of 2019 H.R. 861 - End Surprise Billing Act H.R. 3630 - No Surprises Act H.R. 3502 - Protecting People from Surprise Medical Bills Act H.R. 2550 - Prevent BLEEDing Act of 2019 H. R. 2143 - Promoting Integrity in Medicare Act of 2019 H. R. 3107 - Improving Seniors' Timely Access to Care Act of 2019 H. R. 1332 - Fair Care Act of 2019 H.R. 2464 - End the Cycle of Violence Act of 2019 S. 1895 - Lower Health Care Costs Act S. 967 - Reducing Costs for Out of Network Services Act S. 1266 - Protecting Patients from Surprise Medical Bills Act S. 1531 - Stopping the Outrageous Practice of Surprise Bills Act S. 1607 - Medical Billing Fairness Act H. R. - 1763/S. 348 - Resident's Physician Shortage Reduction Act S. 1350 - Good Samaritan Health Professionals Act H. R. 2689/S. 1438 - Breast Cancer Research Stamp reauthorization H.R. 4350/S. 3085 - Ambulatory Surgical Center Quality and Access Act of 2019 H.R. 5855 - Bipartisan Solution to Cyclical Violence Act of 2020 H.R. 6953 - Pandemic Responder Service Award Act H.R. 6644/S. 3741 - Telehealth legislation/The Health Care at Home Act H.R. 6365/S. 3559 - Immediate Relief for Rural Facilities Act H.R. 7255 - Coronavirus Health Care Worker Wellness Act S. 3741 - Health Care at Home Act S. 3750/H.R. 6837 - Medicare Accelerated and Advanced Payments Improvement Act H.R.133 - Consolidated Appropriations Act, 2021 Phase 4 COVID-19 relief legislation H. R. 8702 - Holding Providers Harmless from Medicare Cuts During COVID-19 Act Federal Incentive Programs COVID-Safely Returning to Work and School in the Fall COVID-PPE Shortages Mental Health Issues Health Care Disparities Cures 2.0 E/M Global Code Issues Unique Patient Identifier Lower Health Care Costs Act Compromise Bleeding Control for the Injured (Stop The Bleed campaign) Qualified clinical data registry (QCDR) Firearms Safety and Research MACRA Implementation Merit-based Incentive Payment Systems (MIPS) MIPS Value Pathways (MVPs) Alternative Payment Models (APM) Outpatient Prospective Payment System (OPPS) Common Rule Medicare for All National Trauma Systems Legislation Drug Pricing Patient-Centered Outcomes Research Institute (PCORI) Measuring Surgical Quality Medicare Physician Reimbursement Cancer Research and Funding Trauma Research and Funding Opioids/Pain Management Legislation ACS THRIVE (Transforming Health care Resources to Increase Value and Efficiency) Reauthorization of Patient-Centered Outcomes Research Institute (PCORI) 2020 CMS Proposed Fee Schedule Rare earth magnet legislation

Client expense: $308,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE, Veterans Affairs, Dept of (VA)

Drug price monitoring; H.R. 1730, S. 741 The Cancer Drug Parity Act; H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 133, FY 2021 Omnibus and COVID Relief and Response Act.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1730/S. 741 The Cancer Drug Parity Act; H.R. 133, FY 2021 Omnibus and COVID Relief and Response Act.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 1730/S.741 Cancer Issues - Multiple Myeloma

Client expense: $66,733 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Monitoring healthcare regulations and legislation; Palliative Care Hospice Education & Treatment Act PCHETA (H.R 647/S 2080); Cancer Drug Parity Act (H.R. 1730/S. 741); Lymphedema Treatment Act (H.R. 1948/S. 518); Preventing Opportunities for Teen E-Cigarette and Tobacco Addiction (PROTECT) Act" (H.R.2111/S.1048; Title VIII funding

Client expense: $54,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, White House Office

HR 1730/S.741 Cancer Issues - Multiple Myeloma

Client expense: $61,515 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 3630, No Surprises Act; S. 1531, Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019; S. 1895, Lower Health Care Costs Act; H.R. 5800, Ban Surprise Billing Act; H.R. 5826 Consumer Protections Against Surprise Medical Bills Act; H.R. 1730/S 741, the Cancer Drug Parity Act; Texas v US lawsuit implications for protections for people with pre-existing conditions; federal regulation of Short-Term Limited-Duration Insurance (STLDI) and other junk insurance; S. 4469, the COVID-19 Treatment Coverage Act

Client expense: $90,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Advocating for the Clinical TREATMENT Act (H.R. 913) Advocating for the following as part of the next COVID package: Cancer Drug Parity Act (H.R. 1730/S. 741) Coverage for 90 day supply of cancer medications Creating a Special Enrollment Period for Healthcare.gov

Client expense: Not reported · Firm income: $20,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R.1730/S.741 - Cancer Drug Parity Act H.R.2428 - Access to Breast Cancer Diagnosis Act H.R.2777/S.1936 - Protecting Access to Lifesaving Screenings Act H.R.6514 - Worker Health Coverage Protection Act S.4557 - The COVER Act Efforts to reduce surprise medical billing Public and private insurance adjustments and other policy changes due to the COVID-19 emergency, including those impacting the immunocompromised populations Implementation of the Affordable Care Act Policies related to co-pay assistance programs

Client expense: $70,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Natl Institutes of Health (NIH), SENATE

Cancer Drug Parity Act (S.741 / H.R.1730) Resident Physician Shortage Reduction Act of 2019 (S. 348/H.R. 1763) Newborn Screening Saves Lives Reauthorization Act of 2019 (H.R. 2507) Implementation of Patient Protection and Affordable Care Act (P.L. 111-148) Hematology and oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Reimbursement for CAR-T/cellular and gene therapies Issues impacting opioid access/use for patients with hematologic diseases and disorders Issues impacting blood safety/shortages Issues related to convalescent plasma Healthcare Workforce Resilience Act (H.R. 6788/S. 3599) Coronavirus Provider Protection Act (H.R. 7059) Issues related to health equity/disproportionate impact of COVID-19 on minority populations Health Care at Home Act (H.R. 6644/S. 3741) Withdrawal of the United States from the World Health Organization (WHO)

Client expense: $30,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), White House Office

Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, cancer survivorship, federal health care programs, genetic information, cancer, nutrition, tanning beds, clinical trials, skin cancer, cannabis research, and wellness, including: HR 6514, Worker Health Coverage Protection Act HR 1425, Patient Protection and Affordable Care Enhancement Act Issues related to regulations for implementing section 1557 of the Affordable Care Act on anti-discrimination HR 6800, Health and Economic Recovery Omnibus Emergency Solutions Act or The HEROES Act Issues related to the Senate HELP Committee initiative on preparing for future pandemics. Regulatory issues related to telehealth Issues related to surprise medical billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019; Issues relating to curbing health care costs; H.R.647 & S. 2080, the Palliative Care and Hospice Education and Training Act; Anti-cancer medication cost-sharing parity respecting H.R. 1409; A national family caregiving strategy respecting S. 1719 and H.R. 1028; Access to medicines respecting FDA implementation of right to try law; Introduction of the S. 3404 & H.R. 6102, Verifying Accurate Leading-edge IVCT Development Act of 2020 or the VALID Act of 2020; H.R. 4897 & S. 2358 Women and Lung Cancer Research and Preventive Services Act of 2018; H. Res. 282, supporting initiatives to encourage parents and guardians to take measures to prevent sunburns in minors they care for; H.R. 1966 & S 946, the Henrietta Lacks Enhancing Cancer Research Act of 2019, regarding decreasing disparities in access to cancer clinical trials; Additional issues related to reducing health disparities in cancer clinical trials; Issues related to capturing racial and ethnic data demographic data for communities disproportionately affected by coronavirus; H.R. 2222 and S. 1107, the Women and Lung Cancer Research and Preventative Services Act; H.Res. 14 & S.Res. 223, Expressing support for the designation of DIPG Awareness Day H.R. 1730 and S. 741, the Cancer Drug Parity Act; Cannabis research issues, including S. 2032 Cannabidiol and Marihuana Research Expansion Act and S. 2400Expanding Cannabis Research and Information Act ; H.R. 2689 & S. 1438 the Breast Cancer Research Stamp Reauthorization Act H.R. 4078 & S. 2424 EARLY Act Reauthorization of 2019 S. 2497, the Dependent Income Exclusion Act; Issues related to HHS regulation of prescription drug prices and costs; H.R. 4439, Creating Hope Reauthorization Act; H.R. 1730 and S. 741, the Cancer Drug Parity Act; H.R. 6556, the Gabriella Miller Kids First Research Act 2.0; H.R. 4439 & S. 4010, the Creating Hope Reauthorization Act; H.R.6666 & S. 4315, the COVID-19 Testing, Reaching, And Contacting Everyone (TRACE) Act, bill related to support needed data collection efforts to begin to contain coronavirus; Issues related to cancer survivorship and transitions of care from oncology treatment back to primary care; Issues related to improving data collection during the COVID-19 pandemic; and H.Res 1125, which expresses support for prioritizing racial and ethnic diversity in clinical trials for therapies, diagnostics in clinical trials for therapies, diagnostics, and vaccines for COVID -19. S 4557, COVID Enrollment Response Act (Sen. Baldwin)

Client expense: $815,440 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Energy, Dept of, Environmental Protection Agency (EPA), Federal Reserve System, Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), Veterans Affairs, Dept of (VA), White House Office

Access to Breast Cancer Diagnosis (ABCD) Act (S. 3216 / H.R. 2428) Implementation of the Affordable Care Act Surprise medical billing Cancer Drug Parity Act (S. 741 / H.R. 1730) S. 4557, The COVER Act Proposed Rule related to Grandfathered Plans Proposed Rule related to IRS policies for Medicare Care Arrangements Policies related to COVID and immunocompromised populations Policies related to co-pay assistance programs

Client expense: Not reported · Firm income: $40,000

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Natl Institutes of Health (NIH), SENATE

H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 985, Fair Access for Safe and Timely (FAST) Generics Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 986, Protecting American with Preexisting Conditions Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1010, Short-Term, Limited Duration Insurance (STLDI), regarding all bio-pharmaceutical related provisions. H.R. 1323, Rural Hospital Frontier Fairness Act, regarding all bio-pharmaceutical related provisions. H.R. 1385, State Allowance for a Variety of Exchanges (SAVE) Act, regarding all bio-pharmaceutical related provisions. H.R. 1386, Expanded Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act, regarding all bio-pharmaceutical related provisions. H.R. 1409, Transparency in All Health Care Pricing Act, regarding all bio-pharmaceutical related provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions. H.R. 1478, Insulin importation, regarding all bio-pharmaceutical related provisions. H.R. 1503, Orange Book Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1506, Fair and Immediate Release (FAIR) of Generics Act, regarding all bio-pharmaceutical related provisions. H.R. 1520, Purple Book Continuity Act, regarding all bio-pharmaceutical related provisions. H.R. 2011, Protecting Access to Biosimilars Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2038, State-based , Market-Oriented, Prescription Drug Negotiations Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2064, Product Sample reporting, regarding all bio-pharmaceutical related provisions. S. 61, Safe and Affordable Drugs from Canada Act, regarding all bio-pharmaceutical related provisions. S. 97, Affordable and Safe Drug Importation Act, regarding all bio-pharmaceutical related provisions. S. 102, Prescription Drug Price Relief Act, regarding all bio-pharmaceutical related provisions. S. 344/H.R. 990, Hatch-Waxman Integrity Act, regarding all bio-pharmaceutical related provisions. S. 366/H.R. 1188, FLAT Prices Act- Reduced exclusivity period for certain price hikes, regarding all bio-pharmaceutical related provisions. S. 418, FDA Accountability for Public Safety Act, regarding all bio-pharmaceutical related provisions. S. 419, Protecting Americans from Dangerous Opioids Act, regarding all bio-pharmaceutical related provisions. S. 637, CURE High Drug Prices Act, regarding all bio-pharmaceutical related provisions. S. 657, Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. S. 658, Accelerated Drug Approval for Prescription Therapies Act, regarding all bio-pharmaceutical related provisions. S. 659, Biologic Patent Transparency Act, regarding all bio-pharmaceutical related provisions. S. 660, Transparency in Petitions Act, regarding all bio-pharmaceutical related provisions. S. 709, Establishes public dashboard for price and utilization of drugs purchased by federal programs, regarding all bio-pharmaceutical related provisions. S. 741 /H.R. 1730, Cancer Drug Parity Act, regarding all bio-pharmaceutical related provisions. S. 844, Short Competition Act, regarding all bio-pharmaceutical related provisions. S. 977, Transparent Drug Pricing Act of 2019, regarding all bio-pharmaceutical related provisions. S. 989, STEER Act, regarding all bio-pharmaceutical related provisions. S. 1140, A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009, regarding all bio-pharmaceutical related provisions. S.1169, FDA citizen petition, regarding all bio-pharmaceutical related provisions. S. 1209, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications, regarding all bio-pharmaceutical related provisions. H.R. 2115, Public Disclosure of Drug Discounts Act, regarding all bio-pharmaceutical related provisions H.R.2296/S.1391, FAIR Drug Pricing Act, regarding all bio-pharmaceutical related provisions H.R.2700, Lowering Prescription Drug Costs and Extending Community Health Centers and other Health Priorities Act, regarding all bio-pharmaceutical related provisions H.R. 3223, Pharmacy Benefit Manager Accountability Study Act, regarding all bio-pharmaceutical related provisions S. 1361/H.R.2584, Preventive Health Savings Act, regarding all bio-pharmaceutical related provisions S. 1437, DTC Act, regarding all bio-pharmaceutical related provisions S.1532, Pharmacy Benefit Managers Accountability Study Act, regarding all bio-pharmaceutical related provisions S.1636, Ensuring Innovation Act, regarding all bio-pharmaceutical related provisions S. 1664, Prescription Drug Price Reporting Act, regarding all bio-pharmaceutical related provisions S. 1801, Affordable Medications Act, regarding all bio-pharmaceutical related provisions S. 1895, Lowering Health Costs Act, regarding all bio-pharmaceutical related provisions S. 1897, a bill to establish a process for updating the labeling of certain drugs with outdated labeling, regarding all bio-pharmaceutical related provisions S. 1897/H.R. 3523, End Price Gouging for Medications Act, regarding all bio-pharmaceutical related provisions S. 2004, Emergency Access to Insulin Act, regarding all bio-pharmaceutical related provisions H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions H.R 748/S. 3548, Coronavirus Aid, Relief and Economic Security Act (CARES Act), regarding all bio-pharmaceutical provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, regarding all bio-pharmaceutical related provisions

Client expense: $1,600,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)

H.R. 2477 Beneficiary Enrollment Notification and Eligibility Simplification (BENES) Act; S.741/H.R. 1730 Cancer Drug Parity Act.

Client expense: Not reported · Firm income: $30,000

PL 109-417 - Pandemic and All-Hazards Preparedness Act (PAHPA) PL 116-127/H.R. 6201 - Families First Coronavirus Response Act H.R. 6365/S. 3559 - The Immediate Relief for Rural Facilities and Providers Act H.R. 748/S. 3548 - Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 7059: Coronavirus Provider Protection Act S. 1895 - Lower Health Care Costs Act H.R. 5800 - Ban Surprise Billing Act H.R. 5826 - Consumer Protections Against Surprise Medical Bills Act H.R. 3630 - No Surprises Act H. R. 8 - Bipartisan Background Checks Act of 2019 H. R. 1418 - Competitive Health Insurance Reform Act of 2019 S. 668/H.R. 1570 - Removing Barriers to Colorectal Cancer Screening Act of 2019 S. 966 - Medicare Care Coordination Improvement Act of 2019 S. 2372 - VA MISSION Act of 2018 S. 741/H. R. 1730 - Cancer Drug Parity Act of 2019 H. R. 1379 - Ensuring Lasting Smiles Act H. R. 207 - Stop the Violence Act of 2019 H. R. 1841 - Ensuring Access to General Surgery Act of 2019 (and Senate version reintroduction) H. R. 1041 - Critical Access Hospital Relief Act of 2019 H.R. 3656/S. 1350 - ACCESS Act of 2019 H.R. 861 - End Surprise Billing Act H.R. 3630 - No Surprises Act H.R. 3502 - Protecting People from Surprise Medical Bills Act H.R. 2550 - Prevent BLEEDing Act of 2019 H. R. 2143 - Promoting Integrity in Medicare Act of 2019 H. R. 3107 - Improving Seniors' Timely Access to Care Act of 2019 H. R. 1332 - Fair Care Act of 2019 H.R. 2464 - End the Cycle of Violence Act of 2019 S. 1895 - Lower Health Care Costs Act S. 967 - Reducing Costs for Out of Network Services Act S. 1266 - Protecting Patients from Surprise Medical Bills Act S. 1531 - Stopping the Outrageous Practice of Surprise Bills Act S. 1607 - Medical Billing Fairness Act H. R. - 1763/S. 348 - Resident's Physician Shortage Reduction Act S. 1350 - Good Samaritan Health Professionals Act H. R. 2689/S. 1438 - Breast Cancer Research Stamp reauthorization H.R. 4350/S. 3085 - Ambulatory Surgical Center Quality and Access Act of 2019 H.R. 5855 - Bipartisan Solution to Cyclical Violence Act of 2020 H.R. 6953 - Pandemic Responder Service Award Act H.R. 6644/S. 3741 - Telehealth legislation/The Health Care at Home Act H.R. 6365/S. 3559 - Immediate Relief for Rural Facilities Act H.R. 7255 - Coronavirus Health Care Worker Wellness Act S. 3741 - Health Care at Home Act S. 3750/H.R. 6837 - Medicare Accelerated and Advanced Payments Improvement Act Phase 4 COVID-19 relief legislation Federal Incentive Programs COVID-Safely Returning to Work and School in the Fall COVID-PPE Shortages Mental Health Issues Health Care Disparities Cures 2.0 E/M Global Code Issues Unique Patient Identifier Lower Health Care Costs Act Compromise Bleeding Control for the Injured (Stop The Bleed campaign) Qualified clinical data registry (QCDR) Firearms Safety and Research MACRA Implementation Merit-based Incentive Payment Systems (MIPS) MIPS Value Pathways (MVPs) Alternative Payment Models (APM) Outpatient Prospective Payment System (OPPS) Common Rule Medicare for All National Trauma Systems Legislation Drug Pricing Patient-Centered Outcomes Research Institute (PCORI) Measuring Surgical Quality Medicare Physician Reimbursement Cancer Research and Funding Trauma Research and Funding Opioids/Pain Management Legislation ACS THRIVE (Transforming Health care Resources to Increase Value and Efficiency) Reauthorization of Patient-Centered Outcomes Research Institute (PCORI) 2020 CMS Proposed Fee Schedule Rare earth magnet legislation

Client expense: $10,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE, Veterans Affairs, Dept of (VA)

PL 109-417 - Pandemic and All-Hazards Preparedness Act (PAHPA) PL 116-127/H.R. 6201 - Families First Coronavirus Response Act H.R. 6365/S. 3559 - The Immediate Relief for Rural Facilities and Providers Act H.R. 748/S. 3548 - Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 7059: Coronavirus Provider Protection Act S. 1895 - Lower Health Care Costs Act H.R. 5800 - Ban Surprise Billing Act H.R. 5826 - Consumer Protections Against Surprise Medical Bills Act H.R. 3630 - No Surprises Act H. R. 8 - Bipartisan Background Checks Act of 2019 H. R. 1418 - Competitive Health Insurance Reform Act of 2019 S. 668/H.R. 1570 - Removing Barriers to Colorectal Cancer Screening Act of 2019 S. 966 - Medicare Care Coordination Improvement Act of 2019 S. 2372 - VA MISSION Act of 2018 S. 741/H. R. 1730 - Cancer Drug Parity Act of 2019 H. R. 1379 - Ensuring Lasting Smiles Act H. R. 207 - Stop the Violence Act of 2019 H. R. 1841 - Ensuring Access to General Surgery Act of 2019 (and Senate version reintroduction) H. R. 1041 - Critical Access Hospital Relief Act of 2019 H.R. 3656/S. 1350 - ACCESS Act of 2019 H.R. 861 - End Surprise Billing Act H.R. 3630 - No Surprises Act H.R. 3502 - Protecting People from Surprise Medical Bills Act H.R. 2550 - Prevent BLEEDing Act of 2019 H. R. 2143 - Promoting Integrity in Medicare Act of 2019 H. R. 3107 - Improving Seniors' Timely Access to Care Act of 2019 H. R. 1332 - Fair Care Act of 2019 H.R. 2464 - End the Cycle of Violence Act of 2019 S. 1895 - Lower Health Care Costs Act S. 967 - Reducing Costs for Out of Network Services Act S. 1266 - Protecting Patients from Surprise Medical Bills Act S. 1531 - Stopping the Outrageous Practice of Surprise Bills Act S. 1607 - Medical Billing Fairness Act H. R. - 1763/S. 348 - Resident's Physician Shortage Reduction Act S. 1350 - Good Samaritan Health Professionals Act H. R. 2689/S. 1438 - Breast Cancer Research Stamp reauthorization H.R. 4350/S. 3085 - Ambulatory Surgical Center Quality and Access Act of 2019 H.R. 5855 - Bipartisan Solution to Cyclical Violence Act of 2020 H.R. 6953 - Pandemic Responder Service Award Act H.R. 6644/S. 3741 - Telehealth legislation/The Health Care at Home Act H.R. 6365/S. 3559 - Immediate Relief for Rural Facilities Act H.R. 7255 - Coronavirus Health Care Worker Wellness Act S. 3741 - Health Care at Home Act S. 3750/H.R. 6837 - Medicare Accelerated and Advanced Payments Improvement Act Phase 4 COVID-19 relief legislation Federal Incentive Programs COVID-Safely Returning to Work and School in the Fall COVID-PPE Shortages Mental Health Issues Health Care Disparities Cures 2.0 E/M Global Code Issues Unique Patient Identifier Lower Health Care Costs Act Compromise Bleeding Control for the Injured (Stop The Bleed campaign) Qualified clinical data registry (QCDR) Firearms Safety and Research MACRA Implementation Merit-based Incentive Payment Systems (MIPS) MIPS Value Pathways (MVPs) Alternative Payment Models (APM) Outpatient Prospective Payment System (OPPS) Common Rule Medicare for All National Trauma Systems Legislation Drug Pricing Patient-Centered Outcomes Research Institute (PCORI) Measuring Surgical Quality Medicare Physician Reimbursement Cancer Research and Funding Trauma Research and Funding Opioids/Pain Management Legislation ACS THRIVE (Transforming Health care Resources to Increase Value and Efficiency) Reauthorization of Patient-Centered Outcomes Research Institute (PCORI) 2020 CMS Proposed Fee Schedule Rare earth magnet legislation

Client expense: $10,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE, Veterans Affairs, Dept of (VA)

PL 109-417 - Pandemic and All-Hazards Preparedness Act (PAHPA) PL 116-127/H.R. 6201 - Families First Coronavirus Response Act H.R. 6365/S. 3559 - The Immediate Relief for Rural Facilities and Providers Act H.R. 748/S. 3548 - Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 7059: Coronavirus Provider Protection Act S. 1895 - Lower Health Care Costs Act H.R. 5800 - Ban Surprise Billing Act H.R. 5826 - Consumer Protections Against Surprise Medical Bills Act H.R. 3630 - No Surprises Act H. R. 8 - Bipartisan Background Checks Act of 2019 H. R. 1418 - Competitive Health Insurance Reform Act of 2019 S. 668/H.R. 1570 - Removing Barriers to Colorectal Cancer Screening Act of 2019 S. 966 - Medicare Care Coordination Improvement Act of 2019 S. 2372 - VA MISSION Act of 2018 S. 741/H. R. 1730 - Cancer Drug Parity Act of 2019 H. R. 1379 - Ensuring Lasting Smiles Act H. R. 207 - Stop the Violence Act of 2019 H. R. 1841 - Ensuring Access to General Surgery Act of 2019 (and Senate version reintroduction) H. R. 1041 - Critical Access Hospital Relief Act of 2019 H.R. 3656/S. 1350 - ACCESS Act of 2019 H.R. 861 - End Surprise Billing Act H.R. 3630 - No Surprises Act H.R. 3502 - Protecting People from Surprise Medical Bills Act H.R. 2550 - Prevent BLEEDing Act of 2019 H. R. 2143 - Promoting Integrity in Medicare Act of 2019 H. R. 3107 - Improving Seniors' Timely Access to Care Act of 2019 H. R. 1332 - Fair Care Act of 2019 H.R. 2464 - End the Cycle of Violence Act of 2019 S. 1895 - Lower Health Care Costs Act S. 967 - Reducing Costs for Out of Network Services Act S. 1266 - Protecting Patients from Surprise Medical Bills Act S. 1531 - Stopping the Outrageous Practice of Surprise Bills Act S. 1607 - Medical Billing Fairness Act H. R. - 1763/S. 348 - Resident's Physician Shortage Reduction Act S. 1350 - Good Samaritan Health Professionals Act H. R. 2689/S. 1438 - Breast Cancer Research Stamp reauthorization H.R. 4350/S. 3085 - Ambulatory Surgical Center Quality and Access Act of 2019 H.R. 5855 - Bipartisan Solution to Cyclical Violence Act of 2020 H.R. 6953 - Pandemic Responder Service Award Act H.R. 6644/S. 3741 - Telehealth legislation/The Health Care at Home Act H.R. 6365/S. 3559 - Immediate Relief for Rural Facilities Act H.R. 7255 - Coronavirus Health Care Worker Wellness Act S. 3741 - Health Care at Home Act S. 3750/H.R. 6837 - Medicare Accelerated and Advanced Payments Improvement Act Phase 4 COVID-19 relief legislation Federal Incentive Programs COVID-Safely Returning to Work and School in the Fall COVID-PPE Shortages Mental Health Issues Health Care Disparities Cures 2.0 E/M Global Code Issues Unique Patient Identifier Lower Health Care Costs Act Compromise Bleeding Control for the Injured (Stop The Bleed campaign) Qualified clinical data registry (QCDR) Firearms Safety and Research MACRA Implementation Merit-based Incentive Payment Systems (MIPS) MIPS Value Pathways (MVPs) Alternative Payment Models (APM) Outpatient Prospective Payment System (OPPS) Common Rule Medicare for All National Trauma Systems Legislation Drug Pricing Patient-Centered Outcomes Research Institute (PCORI) Measuring Surgical Quality Medicare Physician Reimbursement Cancer Research and Funding Trauma Research and Funding Opioids/Pain Management Legislation ACS THRIVE (Transforming Health care Resources to Increase Value and Efficiency) Reauthorization of Patient-Centered Outcomes Research Institute (PCORI) 2020 CMS Proposed Fee Schedule Rare earth magnet legislation

Client expense: $260,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE, Veterans Affairs, Dept of (VA)

PL 109-417 - Pandemic and All-Hazards Preparedness Act (PAHPA) PL 116-127/H.R. 6201 - Families First Coronavirus Response Act H.R. 6365/S. 3559 - The Immediate Relief for Rural Facilities and Providers Act H.R. 748/S. 3548 - Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 7059: Coronavirus Provider Protection Act S. 1895 - Lower Health Care Costs Act H.R. 5800 - Ban Surprise Billing Act H.R. 5826 - Consumer Protections Against Surprise Medical Bills Act H.R. 3630 - No Surprises Act H. R. 8 - Bipartisan Background Checks Act of 2019 H. R. 1418 - Competitive Health Insurance Reform Act of 2019 S. 668/H.R. 1570 - Removing Barriers to Colorectal Cancer Screening Act of 2019 S. 966 - Medicare Care Coordination Improvement Act of 2019 S. 2372 - VA MISSION Act of 2018 S. 741/H. R. 1730 - Cancer Drug Parity Act of 2019 H. R. 1379 - Ensuring Lasting Smiles Act H. R. 207 - Stop the Violence Act of 2019 H. R. 1841 - Ensuring Access to General Surgery Act of 2019 (and Senate version reintroduction) H. R. 1041 - Critical Access Hospital Relief Act of 2019 H.R. 3656/S. 1350 - ACCESS Act of 2019 H.R. 861 - End Surprise Billing Act H.R. 3630 - No Surprises Act H.R. 3502 - Protecting People from Surprise Medical Bills Act H.R. 2550 - Prevent BLEEDing Act of 2019 H. R. 2143 - Promoting Integrity in Medicare Act of 2019 H. R. 3107 - Improving Seniors' Timely Access to Care Act of 2019 H. R. 1332 - Fair Care Act of 2019 H.R. 2464 - End the Cycle of Violence Act of 2019 S. 1895 - Lower Health Care Costs Act S. 967 - Reducing Costs for Out of Network Services Act S. 1266 - Protecting Patients from Surprise Medical Bills Act S. 1531 - Stopping the Outrageous Practice of Surprise Bills Act S. 1607 - Medical Billing Fairness Act H. R. - 1763/S. 348 - Resident's Physician Shortage Reduction Act S. 1350 - Good Samaritan Health Professionals Act H. R. 2689/S. 1438 - Breast Cancer Research Stamp reauthorization H.R. 4350/S. 3085 - Ambulatory Surgical Center Quality and Access Act of 2019 H.R. 5855 - Bipartisan Solution to Cyclical Violence Act of 2020 H.R. 6953 - Pandemic Responder Service Award Act H.R. 6644/S. 3741 - Telehealth legislation/The Health Care at Home Act H.R. 6365/S. 3559 - Immediate Relief for Rural Facilities Act H.R. 7255 - Coronavirus Health Care Worker Wellness Act S. 3741 - Health Care at Home Act S. 3750/H.R. 6837 - Medicare Accelerated and Advanced Payments Improvement Act Phase 4 COVID-19 relief legislation Federal Incentive Programs COVID-Safely Returning to Work and School in the Fall COVID-PPE Shortages Mental Health Issues Health Care Disparities Cures 2.0 E/M Global Code Issues Unique Patient Identifier Lower Health Care Costs Act Compromise Bleeding Control for the Injured (Stop The Bleed campaign) Qualified clinical data registry (QCDR) Firearms Safety and Research MACRA Implementation Merit-based Incentive Payment Systems (MIPS) MIPS Value Pathways (MVPs) Alternative Payment Models (APM) Outpatient Prospective Payment System (OPPS) Common Rule Medicare for All National Trauma Systems Legislation Drug Pricing Patient-Centered Outcomes Research Institute (PCORI) Measuring Surgical Quality Medicare Physician Reimbursement Cancer Research and Funding Trauma Research and Funding Opioids/Pain Management Legislation ACS THRIVE (Transforming Health care Resources to Increase Value and Efficiency) Reauthorization of Patient-Centered Outcomes Research Institute (PCORI) 2020 CMS Proposed Fee Schedule Rare earth magnet legislation

Client expense: $260,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE, Veterans Affairs, Dept of (VA)

H.R. 1730/S. 741 The Cancer Drug Parity Act; H.R. 6800, The HEROES Act.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Drug price monitoring; H.R. 1730, S. 741 The Cancer Drug Parity Act; H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 6800, The HEROES Act.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 1730/S.741 Cancer Issues - Multiple Myeloma

Client expense: $61,515 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 748, CARES Act H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 985: FAST Generics Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R.1730, Cancer Drug Parity Act of 2019 H.R. 4100: DISARM Act of 2019 - Provisions related to antimicrobial drug development H.R. 5239: Prescription Drug Price Reporting Act - Provisions related to prescription drug pricing transparency S1872/HR5076, Protecting Seniors Through Immunization Act H.R. 5668: MODERN Labeling Act of 2020 - Provisions related to prescription drug labeling H.R. 6019: Cure the Coronavirus Act - Provisions related to FDA prescription drug approvals H.R. 6080: Preventing Drug Shortages Act - Provisions related to prescription drug shortage reporting requirements H.R. 6222: Ensuring Affordable COVID-19 Preventive Care Act of 2020 - Provisions related to prescription drug pricing and access H.R. 6231: Ensuring Access to COVID-19 Preventive Care Act of 2020 - Provisions related to prescription drug pricing and access H.R. 6258: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2019 - Provisions related to reciprocity H.R. 6260: Reciprocity Ensures Streamlined Use of Lifesaving Treatments for Coronavi-rus Patients Act of 2020 - Provisions related to FDA prescription drug marketing approvals H.R. 6390: To require the President to use authorities under the Defense Production Act of 1950 to require emergency production of medical equipment to address the COVID-19 outbreak - Provisions related to the Defense Production Act H.R. 6410: To direct the President to use authority under the Defense Production Act of 1950 to ensure an adequate supply equipment necessary for limiting the spread of COVID-19 - Provisions related to the Defense Production Act H.R. 6450: Price Gouging Prevention Act - Provisions related to prescription drug and medical device pricing H.R. 6457: Disaster and Emergency Pricing Abuse Prevention Act - Provisions related to prescription drug and medical device pricing H.R. 6472: COVID-19 Price Gouging Prevention Act - Provisions related to prescription drug and medical device pricing HR6711, Medical Supply Transparency and Delivery Act, DPA impact on Rx manufacturers H.R. 6906: Health Care Emergency Guarantee Act - Provisions related to prescription drug access and cost sharing H.R. 7269: To amend the Federal Food, Drug, and Cosmetic Act to establish a time-limited provisional approval pathway, subject to specific obligations, for certain drugs and biological products, and for other purposes - Provisions related to FDA provisional approval pathways H.R. 7288: To direct the Secretary of Health and Human Services and other Federal officials to compile into a searchable database information relating to Federal support for biomedical research and development related to COVID-19, and for other purposes - Provisions related to prescription drug research and development and transparency H.R. 7296: To require any COVID-19 drug developed in whole or in part with Federal support to be affordable and accessible by prohibiting monopolies and price gouging, and for other purposes - Provisions related to prescription drug pricing and transparency S. 61: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation S. 73: End Taxpayer Subsidies for Drug Ads Act - Provisions related to direct-to-consumer prescription drug advertising S. 658: Accelerated Drug Approval for Prescription Therapies Act or the ADAPT Act - Provisions related to accelerated approval S. 1384: Prescription Drug Rebate Reform Act of 2019 - Provisions related to prescription drug pricing and negotiated rebates S. 1391: FAIR Drug Pricing Act of 2019 - Provisions related to prescription drug pricing and transparency S. 1437: Drug-price Transparency in Communications (DTC) Act - Provisions related to direct-to-consumer prescription drug advertising S. 1532: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 1712: DISARM Act of 2019 - Provisions related to antimicrobial drug development S. 2161: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2019 - Provisions related to reciprocity S. 2304: Strategies To Address Antibiotic Resistance Act - Provisions related to antimicrobial resistance (AMR) and other issues S. 2723: Mitigating Emergency Drug Shortages Act - Provisions related to prescription drug pricing transparency and other provisions S. 3162: Affordable Drug Manufacturing Act of 2019 - Provisions related to prescription drug manufacturing S. 3166: Prescription Drug Affordability and Access Act - Provisions related to prescription drug pricing S. 3384: Lowering Prescription Drug Prices for America's Seniors and Families Act of 2020 - Provisions related to prescription drug price negotiation, importation, and other issues S. 3439: Lower Health Insurance Deductibles Act - Provisions related to prescription drug pricing and insurance plan design S. 3432: Securing America's Medicine Cabinet Act of 2020 - Provisions related to advanced manufacturing and prescription drugs S. 3545: Reciprocity Ensures Streamlined Use of Lifesaving Treatments for Corona-virus Patients Act of 2020 - Provisions related to FDA prescription drug marketing approvals S3780, HOME Act S. 3872: Promising Pathway Act - Provisions related to FDA provisional approval pathways Transparency policy issues S. 3932: A bill to direct the Secretary of Defense to carry out a pilot program under the TRICARE pharmacy benefits program - Provisions related to DoD TRICARE pharmacy benefits program S. 4010: A bill to amend the Federal Food, Drug, and Cosmetic Act to make permanent the authority of the Secretary of Health and Human Services to issue priority review vouchers to encourage treatments for rare pediatric diseases - Provisions related to priority review vouchers H.R. 7288: Taxpayer Research and Coronavirus Knowledge (TRACK) Act of 2020 - Provisions related to database of federal biomedical investment information for COVID-19 H.R. 7296: Make Medicines Affordable by Preventing Pandemic Pricegouging (MMAPPP) Act of 2020 Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2020 (discussion draft) Proclamation Suspending Entry of Aliens Who Present a Risk to the U.S. Labor Market Following the Coronavirus Outbreak (June 22, 2020) Department of Homeland Security cybersecurity policy issues HHS PREP Act declaration relating to COVID-19 Drug cost and pricing policy issues Drug importation and counterfeiting policy issues HHS Safe Importation Action Plan Prescription drug take back and secure disposal policy issues Expanded access policy issues Antimicrobial resistance (AMR) policy issues High deductible health plans/HSA policy issues Sharing of truthful and non-misleading information about medicines with healthcare professionals and payors FDA modernization policy issues PDUFA policy issues 340B drug discount program policy issues Bipartisan Budget Act of 2018 (Public Law 115-123) - Part D provisions Patient assistance program policy issues Foreign manufacturing policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues Regulatory efficiencies policy issues COVID-19 policy issues Proposed Rule; Importation of Prescription Drugs (RIN 0910-AI45) Buy America and other associated issues related to procurement and sourcing of finished product and active pharmaceutical ingredients CARES ACT-Monograph Reform Support for Arthritis Caucus

Client expense: $870,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)

Access to Breast Cancer Diagnosis (ABCD) Act (S. 3216 / H.R. 2428) Implementation of the Affordable Care Act Surprise medical billing H.R. 6514, the Worker Health Coverage Protection Act Insurance provisions of COVID packages Cancer Drug Parity Act (S. 741 / H.R. 1730)

Client expense: Not reported · Firm income: $40,000

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 1426, Patient Protection and Affordable Care Enhancement Act; H.R. 3630, No Surprises Act; S. 1531, Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019; S. 1895, Lower Health Care Costs Act; H.R. 5800, Ban Surprise Billing Act; H.R. 5826 Consumer Protections Against Surprise Medical Bills Act; H.R. 6201 Families First Coronavirus Response Act; H.R. 6704 Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020; H.R. 1730/S 741, the Cancer Drug Parity Act; H.R. 6674, Medicare Crisis Program Act; HR 6514, the Worker Health Coverage Protection Act, Texas v US lawsuit implications for protections for people with pre-existing conditions; federal regulation of Short-Term Limited-Duration Insurance (STLDI)

Client expense: $130,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Cancer Drug Parity Act (S.741 / H.R.1730) Resident Physician Shortage Reduction Act of 2019 (S. 348/H.R. 1763) Newborn Screening Saves Lives Reauthorization Act of 2019 (H.R. 2507) Implementation of Patient Protection and Affordable Care Act (P.L. 111-148) Hematology and oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Reimbursement for CAR-T/cellular and gene therapies Issues impacting opioid access/use for patients with hematologic diseases and disorders Issues impacting blood safety/shortages Issues related to convalescent plasma Healthcare Workforce Resilience Act (H.R. 6788/S. 3599) Coronavirus Provider Protection Act (H.R. 7059) H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act Issues related to health equity/disproportionate impact of COVID-19 on minority populations

Client expense: $30,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, White House Office

Advocating for the Clinical TREATMENT Act (H.R. 913) Advocating for the following as part of the next COVID package: Cancer Drug Parity Act (H.R. 1730/S. 741) Coverage for 90 day supply of cancer medications Creating a Special Enrollment Period for Healthcare.gov

Client expense: Not reported · Firm income: $20,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R.1730/S.741 - Cancer Drug Parity Act H.R.2428 - Access to Breast Cancer Diagnosis Act H.R.2777/S.1936 - Protecting Access to Lifesaving Screenings Act H.R.6514 - Worker Health Coverage Protection Act Efforts to reduce surprise medical billing Public and private insurance adjustments and other policy changes due to the COVID-19 emergency Implementation of the Affordable Care Act

Client expense: $60,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE

H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 985, Fair Access for Safe and Timely (FAST) Generics Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 986, Protecting American with Preexisting Conditions Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1010, Short-Term, Limited Duration Insurance (STLDI), regarding all bio-pharmaceutical related provisions. H.R. 1323, Rural Hospital Frontier Fairness Act, regarding all bio-pharmaceutical related provisions. H.R. 1385, State Allowance for a Variety of Exchanges (SAVE) Act, regarding all bio-pharmaceutical related provisions. H.R. 1386, Expanded Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act, regarding all bio-pharmaceutical related provisions. H.R. 1409, Transparency in All Health Care Pricing Act, regarding all bio-pharmaceutical related provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions. H.R. 1478, Insulin importation, regarding all bio-pharmaceutical related provisions. H.R. 1503, Orange Book Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1506, Fair and Immediate Release (FAIR) of Generics Act, regarding all bio-pharmaceutical related provisions. H.R. 1520, Purple Book Continuity Act, regarding all bio-pharmaceutical related provisions. H.R. 2011, Protecting Access to Biosimilars Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2038, State-based , Market-Oriented, Prescription Drug Negotiations Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2064, Product Sample reporting, regarding all bio-pharmaceutical related provisions. S. 61, Safe and Affordable Drugs from Canada Act, regarding all bio-pharmaceutical related provisions. S. 97, Affordable and Safe Drug Importation Act, regarding all bio-pharmaceutical related provisions. S. 102, Prescription Drug Price Relief Act, regarding all bio-pharmaceutical related provisions. S. 344/H.R. 990, Hatch-Waxman Integrity Act, regarding all bio-pharmaceutical related provisions. S. 366/H.R. 1188, FLAT Prices Act- Reduced exclusivity period for certain price hikes, regarding all bio-pharmaceutical related provisions. S. 418, FDA Accountability for Public Safety Act, regarding all bio-pharmaceutical related provisions. S. 419, Protecting Americans from Dangerous Opioids Act, regarding all bio-pharmaceutical related provisions. S. 637, CURE High Drug Prices Act, regarding all bio-pharmaceutical related provisions. S. 657, Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. S. 658, Accelerated Drug Approval for Prescription Therapies Act, regarding all bio-pharmaceutical related provisions. S. 659, Biologic Patent Transparency Act, regarding all bio-pharmaceutical related provisions. S. 660, Transparency in Petitions Act, regarding all bio-pharmaceutical related provisions. S. 709, Establishes public dashboard for price and utilization of drugs purchased by federal programs, regarding all bio-pharmaceutical related provisions. S. 741 /H.R. 1730, Cancer Drug Parity Act, regarding all bio-pharmaceutical related provisions. S. 844, Short Competition Act, regarding all bio-pharmaceutical related provisions. S. 977, Transparent Drug Pricing Act of 2019, regarding all bio-pharmaceutical related provisions. S. 989, STEER Act, regarding all bio-pharmaceutical related provisions. S. 1140, A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009, regarding all bio-pharmaceutical related provisions. S.1169, FDA citizen petition, regarding all bio-pharmaceutical related provisions. S. 1209, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications, regarding all bio-pharmaceutical related provisions. H.R. 2115, Public Disclosure of Drug Discounts Act, regarding all bio-pharmaceutical related provisions H.R.2296/S.1391, FAIR Drug Pricing Act, regarding all bio-pharmaceutical related provisions H.R.2700, Lowering Prescription Drug Costs and Extending Community Health Centers and other Health Priorities Act, regarding all bio-pharmaceutical related provisions H.R. 3223, Pharmacy Benefit Manager Accountability Study Act, regarding all bio-pharmaceutical related provisions S. 1361/H.R.2584, Preventive Health Savings Act, regarding all bio-pharmaceutical related provisions S. 1437, DTC Act, regarding all bio-pharmaceutical related provisions S.1532, Pharmacy Benefit Managers Accountability Study Act, regarding all bio-pharmaceutical related provisions S.1636, Ensuring Innovation Act, regarding all bio-pharmaceutical related provisions S. 1664, Prescription Drug Price Reporting Act, regarding all bio-pharmaceutical related provisions S. 1801, Affordable Medications Act, regarding all bio-pharmaceutical related provisions S. 1895, Lowering Health Costs Act, regarding all bio-pharmaceutical related provisions S. 1897, a bill to establish a process for updating the labeling of certain drugs with outdated labeling, regarding all bio-pharmaceutical related provisions S. 1897/H.R. 3523, End Price Gouging for Medications Act, regarding all bio-pharmaceutical related provisions S. 2004, Emergency Access to Insulin Act, regarding all bio-pharmaceutical related provisions H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions H.R 748/S. 3548, Coronavirus Aid, Relief and Economic Security Act (CARES Act), regarding all bio-pharmaceutical provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, regarding all bio-pharmaceutical related provisions

Client expense: $2,160,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)

Monitoring healthcare regulations and legislation; Palliative Care Hospice Education & Treatment Act PCHETA (H.R 647/S 2080); Cancer Drug Parity Act (H.R. 1730/S. 741); Lymphedema Treatment Act (H.R. 1948/S. 518); Preventing Opportunities for Teen E-Cigarette and Tobacco Addiction (PROTECT) Act" (H.R.2111/S.1048; Title VIII funding

Client expense: $90,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, White House Office